Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026595 | 0.89 | MEN1 (0.37) | MEN1KMT2AGAACYP2D6KCNH2 | |
| SCHEMBL23278004 | 0.82 | HRH3 (0.39) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL4724913 | 0.81 | PIK3CD (0.47) | KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL4723629 | 0.81 | PIK3CD (0.47) | KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL4038010 | 0.80 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL19044557 | 0.80 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL19044559 | 0.80 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL1303572 | 0.79 | ATM (0.41) | MEN1KMT2AGAA | |
| SCHEMBL1613168 | 0.79 | ATM (0.41) | MEN1KMT2AGAA | |
| SCHEMBL19517200 | 0.79 | ATM (0.41) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | MEN1 218/4885KMT2A 2976/4885GAA 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.